Humira tops list of drugs with unwarranted US price hikesAbbVie’s Humira heads a list of seven medicines that collectively contributed to a $5.1 billion increase in US Share XHumira tops list of drugs with unwarranted US price hikeshttps://pharmaphorum.com/news/humira-tops-list-of-drugs-with-unwarranted-us-price-hikes/
After Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VCMichael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive Share XAfter Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VChttps://pharmaphorum.com/news/after-alzheimers-trial-woes-biogens-rd-chief-quits-to-head-up-biotech-vc/
Last BACE bombs: Eisai, Biogen give up on elenbecestatThe final BACE inhibitor in clinical testing for Alzheimer’s disease – Eisai and Biogen’s elenbecestat – has been Share XLast BACE bombs: Eisai, Biogen give up on elenbecestathttps://pharmaphorum.com/news/last-bace-bombs-eisai-biogen-give-up-on-elenbecestat/
Who will be the biggest pharma players in orphan drugs?New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Share XWho will be the biggest pharma players in orphan drugs?https://pharmaphorum.com/views-analysis-sales-marketing/who-will-be-the-biggest-pharma-players-in-orphan-drugs/
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarNovartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar Share XNovartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarhttps://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/
Under threat from Novartis, Biogen hails new data from SMA drug SpinrazaUnder threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for Share XUnder threat from Novartis, Biogen hails new data from SMA drug Spinrazahttps://pharmaphorum.com/news/under-threat-from-novartis-biogen-hails-new-data-from-sma-drug-spinraza/
AbbVie makes case for Humira follow-on upadacitinib at EULARThe summer medical conference season is well and truly upon us and much of the focus this week Share XAbbVie makes case for Humira follow-on upadacitinib at EULARhttps://pharmaphorum.com/news/abbvie-makes-case-for-humira-follow-on-upadacitinib-at-eular/
NHS chief hails SMA drug deal – and was that a swipe at Vertex?Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s Share XNHS chief hails SMA drug deal – and was that a swipe at Vertex?https://pharmaphorum.com/news/nhs-chief-hails-sma-drug-deal-and-was-that-a-swipe-at-vertex/
Biogen’s R&D strategy fails to impress after Alzheimer’s trial flopThe dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s Share XBiogen’s R&D strategy fails to impress after Alzheimer’s trial flophttps://pharmaphorum.com/news/biogens-rd-strategy-fails-to-impress-after-alzheimers-trial-flop/
